Search
News & Events
Experts Pledge Global Assault on Kids’ CancerA global plan to tackle one of the most aggressive types of childhood brain tumours will be developed as a result of a meeting of international experts in WA.

News & Events
Beyond the horizon: improving cancer outcomes for Indigenous childrenDr Jessica Buck, a researcher at The Kids Research Institute Australia Cancer Centre and a Kamilaroi woman, is on a mission to address the unique challenges faced by Aboriginal and Torres Strait Islander children with cancer.

News & Events
Lab results confirm promise of new immunotherapy gel for kids cancerNewly published research from The Kids Research Institute Australia and The University of Western Australia has found a gel applied during surgery to treat sarcoma tumours is both safe and highly effective at preventing the cancer from growing back.

News & Events
Replication of rare aggressive brain cancer could pave the way for better treatmentsIn an Australian-first, The Kids Research Institute Australia researchers have developed a new tool that could improve outcomes for children with a highly aggressive type of brain cancer.

News & Events
'Natural killers' potential new cancer weaponThe Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.
Research
The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness programTranscriptional cofactors of the ETO family are recurrent fusion partners in acute leukemia. We characterized the ETO2 regulome by integrating transcriptomic and chromatin binding analyses in human erythroleukemia xenografts and controlled ETO2 depletion models. We demonstrate that beyond its well-established repressive activity, ETO2 directly activates transcription of MYB, among other genes.
Research
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective mannerChemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard chemotherapy regimens has improved response rates and increased survival in some cancers. However, most patients do not respond to treatment and immune checkpoint therapy can cause severe side effects. Therefore, there is a need for alternative immunomodulatory drugs that enhance chemotherapy.
Research
Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology centerOptic pathway gliomas (OPGs) are associated with significant risk of visual and endocrine morbidity, but data on long-term outcomes in symptomatic patients is sparse. This study reviews the clinical course, disease progression, survival outcomes and long-term sequelae in pediatric patients with symptomatic OPGs in our institution over three decades.
Research
A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymomaZFTA-RELA (formerly known as c11orf-RELA) fused supratentorial ependymoma has been recognized as a novel entity in the 2016 WHO classification of CNS tumors and further defined in the recent 2021 edition.
Research
Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy responseBoth fetal and tumor tissue microenvironments display immunosuppressive features characterized by the presence of specific immunomodulatory stromal and immune cell populations. Recently, we discovered shared microenvironments between hepatocellular carcinoma and fetal tissues and described this phenomenon as an oncofetal ecosystem.